Back to Search
Start Over
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
- Source :
-
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Aug; Vol. 197, pp. 110329. Date of Electronic Publication: 2024 May 19. - Publication Year :
- 2024
-
Abstract
- Background: Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m <superscript>2</superscript> q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m <superscript>2</superscript> but high toxicity compromises its delivery.<br />Aim: Cisplatin fractionation may allow, by decreasing the peak serum concentration, to decrease toxicity. To date, no direct comparison was done of HD-Cis versus fractionated high dose cisplatin (FHD-Cis).<br />Methods: This is a multi-institutional randomized phase II trial, stratified on postoperative or definitive chemoradiotherapy, comparing HD-Cis to FHD-Cis (25 mg/m <superscript>2</superscript> /d d1-4 q3w for 3 cycles) in patients with LA-HNSCC. The primary endpoint was the cumulative delivered cisplatin dose.<br />Results: Between December 2015 and April 2018, 124 patients were randomized. Median cisplatin cumulative delivered dose was 291 mg/m <superscript>2</superscript> (IQR: 251;298) in the FHD-Cis arm and 274 mg/m <superscript>2</superscript> (IQR: 198;295) in the HD-Cis arm (P = 0.054). The proportion of patients receiving a third cycle of cisplatin was higher, with a lower proportion of grade 3-4 acute AEs in the FHD-Cis arm compared to the HD-Cis arm: 81 % vs. 64 % (P = 0.04) and 10 % vs. 17 % (P = 0.002), respectively. With a median follow-up of 48 months (IQR: 41;55), locoregional failure rate, PFS and OS were similar between the two arms.<br />Conclusion: Although the primary endpoint was not met, FHD-Cis allowed more cycles of cisplatin to be delivered with lower toxicity, when compared to SOC. FHD-Cis concurrently with RT is a treatment option which deserves further consideration.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Humans
Male
Middle Aged
Female
Aged
Antineoplastic Agents therapeutic use
Antineoplastic Agents administration & dosage
Adult
Cisplatin administration & dosage
Head and Neck Neoplasms radiotherapy
Head and Neck Neoplasms pathology
Head and Neck Neoplasms therapy
Head and Neck Neoplasms drug therapy
Dose Fractionation, Radiation
Chemoradiotherapy methods
Squamous Cell Carcinoma of Head and Neck radiotherapy
Squamous Cell Carcinoma of Head and Neck therapy
Squamous Cell Carcinoma of Head and Neck drug therapy
Squamous Cell Carcinoma of Head and Neck pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0887
- Volume :
- 197
- Database :
- MEDLINE
- Journal :
- Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38768714
- Full Text :
- https://doi.org/10.1016/j.radonc.2024.110329